Literature DB >> 36254027

A nomogram model of postoperative prognosis for metastatic lung adenocarcinoma: A study based on the SEER database.

Xiaowei Tie1, Lianlian Chen, Xiaomin Li, Wenjuan Zha, Yangchen Liu.   

Abstract

We have observed that patients with metastatic lung adenocarcinoma can obtain survival benefits from surgical resection of the primary tumor. A model was developed to evaluate the prognosis of patients. The patients with metastatic lung adenocarcinoma were identified in the Surveillance, Epidemiology, and End Results database and divided into surgery group and non-surgical group. Through Kaplan-Meier analysis, the survival rate of the non-surgical group was found to be significantly lower no matter before or after propensity score matching. One thousand one hundred and seventy surgical patients were divided into a training group and a verification group. In the training group, univariate and multivariate Cox models were used to explore the prognostic factors, and logistic regression was used to establish a nomogram based on significant predictors. In total, 12,228 patients with metastatic lung adenocarcinoma were recognized; primary tumor surgery accounted for 9.5%. After propensity score matching, the median survival time of 2 groups was significantly different. For the training group, univariate and multivariate COX analysis was conducted, and a nomogram was constructed. Acceptable agreement has been achieved between the predicted and observed survival rates, and the nomogram can divide patients with metastatic lung adenocarcinoma into different risk groups and predict their prognostic survival rate.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2022        PMID: 36254027      PMCID: PMC9575752          DOI: 10.1097/MD.0000000000031083

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  22 in total

1.  Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer.

Authors:  Yoshihisa Shimada; Hisashi Saji; Koichi Yoshida; Masatoshi Kakihana; Hidetoshi Honda; Masaharu Nomura; Jitsuo Usuda; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

2.  Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode.

Authors:  Ozcan Birim; A Pieter Kappetein; Marco Waleboer; John P A Puvimanasinghe; Marinus J C Eijkemans; Ewout W Steyerberg; Michel I M Versteegh; Ad J J C Bogers
Journal:  J Thorac Cardiovasc Surg       Date:  2006-09       Impact factor: 5.209

3.  Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer.

Authors:  Wenhua Liang; Li Zhang; Gening Jiang; Qun Wang; Lunxu Liu; Deruo Liu; Zheng Wang; Zhihua Zhu; Qiuhua Deng; Xinguo Xiong; Wenlong Shao; Xiaoshun Shi; Jianxing He
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

4.  Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.

Authors:  Sun Young Kim; Min Joo Yoon; Young Iee Park; Mi Jung Kim; Byung-Ho Nam; Sook Ryun Park
Journal:  Gastric Cancer       Date:  2017-08-21       Impact factor: 7.370

Review 5.  Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.

Authors:  Nicholas P Giustini; Ah-Reum Jeong; James Buturla; Lyudmila Bazhenova
Journal:  Clin Chest Med       Date:  2020-06       Impact factor: 2.878

6.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 7.  Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.

Authors:  Pablo Martinez; Solange Peters; Timothy Stammers; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2019-01-14       Impact factor: 12.531

8.  Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study.

Authors:  Yang Zhang; Difan Zheng; Juntao Xie; Yuan Li; Yiyang Wang; Chenguang Li; Jiaqing Xiang; Yawei Zhang; Hong Hu; Yihua Sun; Haiquan Chen
Journal:  Chest       Date:  2018-06-18       Impact factor: 9.410

9.  Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis.

Authors:  Kaitai Liu; Dawei Zheng; GuoDong Xu; Zhennan Du; Shibo Wu
Journal:  PLoS One       Date:  2017-11-10       Impact factor: 3.240

10.  Novel chalcones derivatives with potential antineoplastic activity investigated by docking and molecular dynamics simulations.

Authors:  Raimundo de A M Neto; Cleydson B R Santos; Shayanne V C Henriques; Letícia de O Machado; Jorddy N Cruz; Carlos H T de P da Silva; Leonardo B Federico; Edivaldo H C de Oliveira; Michel P C de Souza; Patrícia N B da Silva; Carlton A Taft; Irlon M Ferreira; Madson R F Gomes
Journal:  J Biomol Struct Dyn       Date:  2020-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.